Macquarie Group
AXSM icon

Macquarie Group’s Axsome Therapeutics AXSM Stock Holding History

Macquarie Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4K Buy
+75
New +$16.3K ﹤0.01% 896
2025
Q4 		– Sell
-1,084,536
Closed -$132M – 920
2025
Q3 		$132M Sell
1,084,536
-53,212
-5% -$5.99M 0.15% 150
2025
Q2 		$119M Buy
1,137,748
+161,488
+17% +$17.1M 0.15% 178
2025
Q1 		$114M Buy
976,260
+12,213
+1% +$1.39M 0.14% 200
2024
Q4 		$81.6M Sell
964,047
-31,240
-3% -$2.87M 0.1% 290
2024
Q3 		$89.4M Sell
995,287
-77,955
-7% -$6.8M 0.1% 283
2024
Q2 		$86.4M Buy
1,073,242
+372,832
+53% +$27.6M 0.1% 266
2024
Q1 		$55.9M Buy
700,410
+672,886
+2,445% +$56.5M 0.06% 396
2023
Q4 		$2.19M Buy
27,524
+6,009
+28% +$402K ﹤0.01% 1197
2023
Q3 		$1.5M Sell
21,515
-24,576
-53% -$1.84M ﹤0.01% 1240
2023
Q2 		$3.31M Buy
46,091
+26,187
+132% +$1.93M ﹤0.01% 1029
2023
Q1 		$1.23M Buy
19,904
+1,498
+8% +$98.4K ﹤0.01% 1312
2022
Q4 		$1.42M Sell
18,406
-9,301
-34% -$556K ﹤0.01% 1315
2022
Q3 		$1.24M Sell
27,707
-6,520
-19% -$326K ﹤0.01% 1371
2022
Q2 		$1.31M Sell
34,227
-5,047
-13% -$160K ﹤0.01% 1412
2022
Q1 		$1.63M Buy
39,274
+12,975
+49% +$402K ﹤0.01% 1428
2021
Q4 		$994K Buy
26,299
+54
+0.2% +$1.99K ﹤0.01% 1556
2021
Q3 		$865K Buy
26,245
+1,608
+7% +$62.7K ﹤0.01% 1618
2021
Q2 		$1.66M Buy
24,637
+2,946
+14% +$177K ﹤0.01% 1471
2021
Q1 		$1.23M Buy
21,691
+2,751
+15% +$194K ﹤0.01% 1344
2020
Q4 		$1.54M Buy
18,940
+17,772
+1,522% +$1.33M ﹤0.01% 1182
2020
Q3 		$83K Hold
1,168
– – ﹤0.01% 1831
2020
Q2 		$96K Buy
+1,168
New +$89.9K ﹤0.01% 1760

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Macquarie Group's AXSM Position: Q2 2026 in Review

Macquarie Group opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 75 shares worth $18.4K. The stake represents ﹤0.01% of the portfolio and ranks #896 among its holdings. This is a return to the name: Macquarie Group previously reported a position in AXSM as recently as Q3 2025.

Macquarie Group first reported a position in AXSM in Q2 2020 and has held it in 23 quarters since. The position peaked at $132M in Q3 2025. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Macquarie Group held 75 shares of Axsome Therapeutics worth $18.4K as of Q2 2026.
  • Axsome Therapeutics was a new Macquarie Group position in Q2 2026.
  • Axsome Therapeutics made up ﹤0.01% of Macquarie Group's portfolio in Q2 2026, its #896 holding.
  • Macquarie Group first reported a position in Axsome Therapeutics in Q2 2020 and has held it in 23 quarters since.
  • Macquarie Group's Axsome Therapeutics position peaked at $132M in Q3 2025.
  • 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.